Cancer biology and biochemistry

June 5, 2020 | Duration: 50 mins.

To unlock new therapeutic avenues in cancer, it is critical to understand the molecular bases of this collection of diseases. This virtual event examines different ways in which normal cellular processes are altered in disease development and response to treatment, focusing on EGFR and c-myc.

The talks in this virtual event were originally programmed to take place as an in-person Spotlight Session at the 2020 ASBMB Annual Meeting.


Chair: Michael Sugiyama

The F-box protein FBXL16 upregulates the stability of c-myc oncoprotein by antagonizing FBW7 function
Marion Morel, Wright State University

EGFR signaling in breast cancer requires licensing from separate membrane nanodomains
Michael Sugiyama, Ryerson University

Epigenetic reprogramming driven by metabolic alterations as a mechanism of EGFR — Tyrosine kinase inhibitor resistance in human lung adenocarcinoma
Abhilash Venugopalan, National Cancer Institute